Cell Line News and Research

RSS

Transgenomic, Horizon Discovery collaborate to develop improved genetic diagnostic tests with state of art controls

Transgenomic, Inc. (OTCBB: TBIO), a global biotechnology company advancing personalized medicine in cardiology, oncology, and inherited diseases through diagnostic tests as well as clinical and research services, and Horizon Discovery Ltd. (Horizon), a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced they have entered into a collaboration agreement to develop improved genetic diagnostic tests incorporating state of the art controls.

16 Jan 2014

Demand growing for Porvair Sciences' Chromatrap ChIP assay technology

Porvair Sciences reports strong growing demand for their Chromatrap chromatin immunoprecipitation (ChIP) assay technology from academic groups and biopharmaceutical organisations involved with epigenetic research.

From Chromatrap® - Porvair Sciences Ltd 6 Jan 2014

New study by bioethicists indicates patients give "broad endorsement" to iPSC research

In an early indication of lay opinions on research with induced pluripotent stem cells, which are stem cells made from skin or other tissues, a new study by bioethicists at Johns Hopkins University indicates that despite some ethical concerns, patients give the research "broad endorsement".

6 Jan 2014

Novel multi-kinase inhibitor shows early promise in NSCLC

Researchers have reported promising early data on an investigational drug that targets two tyrosine kinase receptors that drive invasive growth and drug resistance in non-small-cell lung cancer.

9 Dec 2013

IRCM researcher sheds light on inconsistencies between pharmacogenomic studies

A bioinformatics expert at the IRCM, Benjamin Haibe-Kains, recently published an article stressing the importance of standardizing drug screening studies in the prestigious scientific journal Nature. The study supports the need for further development and standardization to improve the reproducibility of drug screening studies, as they are important in identifying new therapeutic agents and their potential combinations with existing drugs.

3 Dec 2013

JHL Biotech installs GE Healthcare's FlexFactory biomanufacturing platform at Hsinchu plant in Taiwan

GE Healthcare Life Sciences and JHL Biotech today announced that GE Healthcare has completed installation of its FlexFactory biomanufacturing platform at JHL Biotech's Research Center and manufacturing plant in Hsinchu, Taiwan.

2 Dec 2013

Enzyme intervenes when cancer-fighting PTEN is bound for cell's protein-destroying machinery

A protector for PTEN, a tumor-thwarting protein often missing in cancer cells, has emerged from research led by scientists at The University of Texas MD Anderson Cancer Center published online at Nature Cell Biology this week.

28 Nov 2013

Research: Human neural stem cells could improve blood flow in critical limb ischemia

New research has shown human neural stem cells could improve blood flow in critical limb ischemia through the growth of new vessels. Critical limb ischemia is a disease that severely obstructs arteries and reduces the blood flow to legs and feet. CLI remains an unmet clinical problem and with an ageing population and the rise in type II diabetes, the incidence of CLI is expected to increase.

27 Nov 2013

Natural compound coumarins exhibit anti-inflammatory as well as anticoagulant activities

New methods for the laboratory-scale synthesis of coumarin-based drugs were developed in a recent study completed at the University of Eastern Finland. In his doctoral thesis, Lic. Phil. Juri Timonen also developed new analytical methods for the fast identification of natural and non-natural coumarins.

26 Nov 2013

Using radiation models to improve cancer therapies: an interview with Adrian Treverton, COO of Xstrahl and Jean-Pierre Wery, President of Crown Bioscience

What we are trying to do is take a cancer model like the PDX model (patient-derived tumor xenograft), which is a human-derived cancer growing in an in vivo model and apply radiation to that model.

From Xstrahl 20 Nov 2013

Cells sticking molecule over-produced in rheumatoid arthritis and cancers

A molecule that helps cells stick together is significantly over-produced in two very different diseases - rheumatoid arthritis and a variety of cancers, including breast and brain tumors, concludes a new study. The scientists who made the discovery also found candidate drugs to inhibit the molecule, cadherin-11, one of which is already in a clinical trial.

14 Nov 2013

Stem cells from Wolfram syndrome patients used to elucidate beta-cell failure pathway in diabetes

Scientists from the New York Stem Cell Foundation Research Institute and Columbia University Medical Center have used stem cells created from the skin of patients with a rare form of diabetes—Wolfram syndrome—to elucidate an important biochemical pathway for beta-cell failure in diabetes. The findings by Linshan Shang and colleagues were published today in Diabetes.

13 Nov 2013

Investigators find potential new target for treatment of low-grade gliomas

Investigators at Johns Hopkins have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers.

7 Nov 2013

miR-137 offers new therapeutic direction for post-stroke depression

MiRNAs likely play an important role in the occurrence and development of depression, and can be used as potential targets for treatment of depression. Studies have shown that miR-137 expression is downregulated in the brain from depression patients with suicidal behavior.

7 Nov 2013

Reinnervate, Oncotest and SBH partner to offer 3D tumour cell screening services

3D cell culture company Reinnervate Ltd today announced partnerships with two oncology-focussed CRO's to offer 3D tumour cell screening services. The CROs, Oncotest GmbH (Freiburg, Germany) and SBH Sciences (Natick, MA, USA) will both offer a new service for clients wishing to try out cancer 3D cell culture screening for the first time or who wish to evaluate new tumour types in their models.

31 Oct 2013

Fatty acid entry into cells happens by diffusion

The current global epidemic of obesity-linked diabetes and its associated consequences -cardiovascular, neurological and renal diseases - is a growing public health problem for which therapeutic options are limited.

23 Oct 2013

EntreMed presents preclinical data for ENMD-2076 in triple-negative breast cancer

EntreMed, Inc., a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced today the presentation of preclinical data from a study to assess the role of p53 family tumor suppressors in mediating response to ENMD-2076 in triple-negative breast cancer (TNBC).

21 Oct 2013